首站-论文投稿智能助手
典型文献
High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma
文献摘要:
Multiple myeloma (MM) is a common malig-nant hematological tumor in adults, which is charac-terized by clonal malignant proliferation of plasma cells in the bone marrow and secretion of a large num-ber of abnormal monoclonal immunoglobulins (M pro-tein), leading to bone destruction, hypercalcemia, an?emia, and renal insufficiency (Alexandrakis et al., 2015;Yang et al., 2018). Since a large number of new drugs, represented by proteasome inhibitors and im-munomodulators, have been successfully used to treat MM, treatment efficacy and survival of patients have been significantly improved. However, due to the high heterogeneity of this disease, patients have responded differently to treatments with these new drugs (Pa-lumbo and Anderson, 2011;Wang et al., 2016;Huang et al., 2020). Growth and survival of MM cells de-pend on the bone marrow microenvironment, espe-cially numerous inflammatory cytokines secreted by myeloma cells and bone marrow stromal cells, such as vascular endothelial growth factor (VEGF), inter-leukin (IL)-6, transforming growth factor-β (TGF-β), and IL-10. These cytokines can promote the growth of myeloma cells, induce angiogenesis, and inhibit antitumor immunity, and are often linked to patient prognosis (Kumar et al., 2017).
文献关键词:
作者姓名:
Xiaoyan YUE;Linlin HUANG;Yang YANG;Yi ZHAO;Donghua HE;Xiaoyan HAN;Gaofeng ZHENG;Yi LI;Enfan ZHANG;Zhen CAI;Xin HUANG;Jingsong HE
作者机构:
Bone Marrow Transplantation Center,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China;Institute of Hematology,Zhejiang University,Hangzhou 310058,China;Zhejiang Laboratory for Systems&Precision Medicine,Zhejiang University Medical Center,Hangzhou 311121,China;Institute of Hematology,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China
引用格式:
[1]Xiaoyan YUE;Linlin HUANG;Yang YANG;Yi ZHAO;Donghua HE;Xiaoyan HAN;Gaofeng ZHENG;Yi LI;Enfan ZHANG;Zhen CAI;Xin HUANG;Jingsong HE-.High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma)[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2022(11):968-974,16-19
A类:
emia,Alexandrakis,munomodulators,lumbo
B类:
High,levels,serum,indicate,disease,progression,extramedullary,involvement,poor,prognosis,multiple,myeloma,Multiple,MM,common,hematological,adults,which,charac,terized,by,malignant,proliferation,plasma,cells,bone,marrow,secretion,large,abnormal,monoclonal,immunoglobulins,tein,leading,destruction,hypercalcemia,renal,insufficiency,Yang,Since,number,new,drugs,represented,proteasome,inhibitors,have,been,successfully,used,efficacy,survival,patients,significantly,improved,However,due,high,heterogeneity,this,responded,differently,treatments,these,Pa,Anderson,Wang,Huang,Growth,pend,microenvironment,espe,cially,numerous,inflammatory,cytokines,secreted,stromal,such,vascular,endothelial,growth,VEGF,inter,leukin,transforming,TGF,These,promote,induce,angiogenesis,antitumor,immunity,are,often,linked,Kumar
AB值:
0.565671
相似文献
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
Haoran Mu;Dongqing Zuo;Jie Chen;Zhigang Liu;Zhuo Wang;Liu Yang;Qihui Shi;Yingqi Hua-Shanghai Bone Tumor Institute and Department of Orthopedics,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Center for Systems Biomedicine,Shanghai Jiao Tong University,Shanghai 200240,China;Shanghai Key Laboratory of Medical Epigenetics and the International Co-laboratory of Medical Epigenetics and Metabolism(MOST),Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer(SMHC)and Institute of Fudan-Minhang Academic Health System,Minhang Hospital,Fudan University,Shanghai 201199,China;Shanghai Engineering Research Center of Biomedical Analysis Reagents,Shanghai 201203,China
NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
Rongfang Wei;Xing Cui;Jie Min;Zigen Lin;Yanyan Zhou;Mengjie Guo;Xiaojuan An;Hao Liu;Siegfried Janz;Chunyan Gu;Hongbo Wang;Ye Yang-Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210022,China;School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Hematology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Division of Hematology and Oncology,Medical College of Wisconsin,Milwaukee,WI 53226,USA;School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai 264005,China;Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264003,China
Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB/IL-6/STAT3 and JNK/PTX3 pathways
Wan Li;Hongqing Cai;Liwen Ren;Yihui Yang;Hong Yang;Jinyi Liu;Sha Li;Yizhi Zhang;Xiangjin Zheng;Wei Tan;Guanhua Du;Jinhua Wang-The State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Beijing 100050,China;Key Laboratory of Drug Target Research and Drug Screen,Institute of Materia Medica,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100050,China;Department of Neurosurgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;State Key Laboratory of Molecular Oncology,Center for Cancer Precision Medicine,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;School of Pharmacy,Xinjiang Medical University,Urumqi 830011,China;Xinjiang Institute of Materia Medica,Urumqi 830004,China
Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis
Jiansong Huang;Xin Huang;Yang Li;Xia Li;Jinghan Wang;Fenglin Li;Xiao Yan;Huanping Wang;Yungui Wang;Xiangjie Lin;Jifang Tu;Daqiang He;Wenle Ye;Min Yang;Jie Jin-Department of Hematology,Key Laboratory of Hematologic Malignancies,Diagnosis and Treatment,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Institute of Hematology,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Obstetrics,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Hematology,Qingdao Municipal Hospital,Qingdao 266000,China;Department of Laboratory Medicine,Affiliated Hangzhou First People's Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Cancer Center Zhejiang University,Hangzhou 310058,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。